Rapid-SF: A rapid whole-blood screen for soluble fibrin monomer

Thrombosis and Haemostasis

Volumn 88, Issue 5, 2002, Pages 773-780

  Hay, Karen L ^a   Bull, Brian S ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Disseminated intravascular coagulation; Fibrin analysis; Paracoagulation; Soluble fibrin; Thrombosis diagnosis

Indexed keywords

ANTICOAGULANT AGENT; FIBRIN; FIBRIN MONOMER; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; DIAGNOSTIC AGENT; THROMBIN;

ANALYZER; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD CLOTTING; BLOOD EXAMINATION; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISSEMINATED INTRAVASCULAR CLOTTING; EMERGENCY WARD; HUMAN; LUNG EMBOLISM; MALE; MATHEMATICAL ANALYSIS; METHODOLOGY; OPERATING ROOM; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ASSAY; RELIABILITY; SCREENING; SENSITIVITY ANALYSIS; THROMBOSIS; WESTERN HEMISPHERE; HOSPITAL INFORMATION SYSTEM; KINETICS; REFERENCE VALUE; SOLUBILITY;

FIBRIN; HEMATOLOGIC TESTS; HUMANS; KINETICS; POINT-OF-CARE SYSTEMS; PROTAMINES; REFERENCE VALUES; SOLUBILITY; THROMBIN; THROMBOSIS;

EID: 0036847589     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613301     Document Type: Article

References (30)

1. Bakker CM. Knot EA. Stibbe J. Wilson JH. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol 1992; 15: 330-5.
2. Ginsberg JS, Siragusa S, Douketis J, Johnston M, Morrat K, Stevens P, Brill-Edwards P, Panju A, Patel A. Evalution of a soluble fibrin assay in patients with suspected deep vein thrombosis. Thromb Haemost 1995; 74 (3): 833-6.
3. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 1999; 82: 673-83.
4. Caliezi C, Fhnfsinn N, Mauron T, Baumgartner I, Sulzer I, Ulrich M, Cottier C, Biasiutti FD, Lämmle B, Wuillemin WA. Performance of a new fibrin monomer assay to exclude deep vein thrombosis in symptomatic outpatients. Thromb Haemost 1999; 81: 50-3.
5. Halvorsen S, Skjønsberg, Ruyter R, Godal HC. Comparison of methods for detecting soluble fibrin in plasma. An in vitro study. Thromb Res 1990; 57: 489-97.
6. Wieding JU, Eisinger G, Køstering H. Determination of soluble fibrin by turbidimetry of its protamine sulfate-induced paracoagulation. J Clin Chem Clin Biochem 1989; 27: 57-63.
7. Wieding JU, Hosius C. Determination of soluble fibrin: A comparison of four different methods. Thromb Res 1992; 65: 745-56.
8. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyma K, Nagaya S, Deguchi H, Mori Y, Kaneko T, Deguchi K, Fujii J, Shiku H. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51: 255-60.
9. Nieuwenhuizen W, Hoegee-De Nobel E, Laterveer R. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma. Thromb Haemost 1992; 68 (3): 273-7.
10. Bredbacka S, Blombäck M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesth Scand 1993; 37: 125-30.
11. Dempfle CE, Pfitzner SA, Dollman M, Huck K, Stehle G, Heene DL. Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb Haemost 1995; 74 (2): 673-9.
12. Bos R, Laterveer-Vreeswijk GH, Lockwood D, Szewczyk K, Nieuwenhuizen W. A new enzyme immunoassay for soluble fibrin in plasma, with a high discriminating power for thrombotic disorders. Thromb Haemost 1999; 81: 54-9.
13. Wada H, Sakuragawa N, Mori Y, Takagi M, Nakasaki T, Shimura M, Hiyoyama K, Nisikawa M, Gabazza EC, Deguchi K, Kazama M, Shiku H. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 1999; 60: 273-8.
14. Bredbacka S, Blombäck M, Wiman B. Soluble fibrin: a predictor for the development and outcome of multiple organ failure. Am J Hematol 1994; 46: 289-94.
15. Brosstad F, Kierulf P, Godal HC. The fibrin-solubilizing effect of fibrinogen as studied by light scattering. Thromb Res 1979; 14: 705-712.
16. Usero JL, Burguillo FJ, Izquierdo C, Del-Arco A, Herraez MA. The fibrinogen-fibrin complex: stoichiometry and negative cooperativity. Thromb Res 1985; 39: 379-86.
17. Siegal S, Castellan Jr. NJ. Nonparametric statistics for the Behavioral Sciences, 2nd edition. New York: McGraw Hill Book Company 1988; 137-43.
18. Royston P. Approximating the Shapiro-Wilk W test for non-normality. Stat Comput 1992; 2: 117-9.
19. Siegal S, Castellan Jr. NJ. Nonparametric statistics for the Behavioral Sciences, 2nd edition. New York: McGraw Hill Book Company 1988; 144-51.
20. Siegal S, Castellan Jr. NJ. Nonparametric statistics for the Behavioral Sciences, 2nd edition. New York: McGraw Hill Book Company 1988; 128-37.
21. Siegal S, Castellan Jr. NJ. Nonparametric statistics for the Behavioral Sciences, 2nd edition. New York: McGraw Hill Book Company 1988; 103-11.
22. Siegal S, Castellan Jr. NJ. Nonparametric statistics for the Behavioral Sciences, 2nd edition. New York: McGraw Hill Book Company 1988; 235-44.
23. Wiltzius P, Dietler G, Kanzig W, Hofmann V, Haberli A, Straub PW. Fibrin aggregation before sol-gel transition. Biophys J 1982; 38: 123-32.
24. Brass EP, Forman WB, Edwards RV, Lindan O. Fibrin formation: the role of the fibrinogen-fibrin monomer complex. Thromb Haemost 1976; 31: 36-48.
25. Horn RG, Hawiger J, Collins RD. Electron Microscopy of fibrin-like precipitate formed during the paracoagulation reaction between soluble fibrin monomer complexes and protamine sulphate. Br J Haematol 1969; 17: 463-6.
26. Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ 1998; 316: 984-7.
27. Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group. WHO Tech Rep Ser 1998; 877: 1-89.
28. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
29. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-7.
30. Lapostolle F, Surget V, Borron SW, Desmaizières M, Sordelet D, Lapandry C, Cupa M, Adnet F. Severe pulmonary embolism associated with air travel. N Engl J Med 2001; 345: 779-783.